◆Co-creation Activities with Tohoku University for Clinical Trial Preparation
Through our co-creation activities with Tohoku University, we are identifying optimal indications for drug candidate compounds and preparing for clinical trials aimed at their practical implementation. This investment will accelerate our clinical trial preparations.

◆Investor Comment
"The co-creation activities between Asahihi Pharmaceutical Co., Ltd. and Tohoku University are proposing new, evidence-based treatment possibilities for optimal indications for drug candidate compounds. We look forward to seeing further progress in this highly socially significant initiative."

Fumihiro Nakamori, Vice President, Investment Department, Tohoku University Venture Partners, Inc.

◆Future Outlook
With this investment, we will further strengthen our clinical development system and co-creation activities with Tohoku University, and continue to advance development aimed at expanding treatment options. We will continue to develop and realize new treatments with the aim of improving the quality of life of patients suffering from illness.